Patent issues relating to hybrid drugs

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 10, 2008, Pages 1191-1194

  Richards, John ^a  

^a Ladas and Parry LLP   (United States)

Author keywords

Hybrid drugs; KSR; Obviousness; Predicatability

Indexed keywords

DRUG; HYBRID DRUG; PIOGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CORD BLOOD STEM CELL; COURT; CRYOPRESERVATION; DECISION MAKING; DRUG INDUSTRY; DRUG LEGISLATION; LAW; LAW SUIT; PATENT; STEM CELL; UNITED STATES;

EID: 56349124231     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.10.1191     Document Type: Article

References (8)

1. Sarkar DP Ramani Y, Bora RS, et al. Process for producing a targeted gene. US5683866; 1997
2. Bhosle D, Bharambe S, Gairola N, Dhaneshwar SS. Mutual prodrug concept: fundamentals and applications. Indian J Pharm Sci 2006; 68: 286-94
3. Examination guidelines for determining obviousness under 35 USC 103 in view of the Supreme Court decision in KSR International Co. v. Teleflex, Inc. Fed Reg 2007; 72(195): 57526-35
4. Breschi MC, Calderone V, Digiacomo M, et al. NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs. J Med Chem 2004; 47(23): 5597-600
5. Hanson RN, Babich JW. Polypharmacophoric agents. US7141573; 2006
6. Weaver DF, Carran JR. Anti-epileptogenic agents. US6930112; 2005
7. Rosen N, Danishefiky S, Ouerfelli O, et al. Methods and compositions for destruction of selected proteins. US6670348; 2003
8. Hulsman N, Medema JP Bos C, et al. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem 2007; 50: 2424-31.